Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy-Reference-Cited by-同舟云学术

Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

Published:2021-02-26 Issue:1 Volume:10 Page:375-389
ISSN:2193-8253
Container-title:Neurology and Therapy
language:en
Short-container-title:Neurol Ther

Author:

Coelho Teresa,Ando Yukio,Benson Merrill D.,Berk John L.,Waddington-Cruz Márcia,Dyck Peter J.,Gillmore Julian D.,Khella Sami L.,Litchy William J.,Obici Laura,Monteiro Cecilia,Tai Li-Jung,Viney Nicholas J.,Buchele Gustavo,Brambatti Michela,Jung Shiangtung W.,St. L. O’Dea Louis,Tsimikas Sotirios,Schneider Eugene,Geary Richard S.,Monia Brett P.,Gertz Morie

Funder

Ionis Pharmaceuticals

Akcea Therapeutics

Publisher

Springer Science and Business Media LLC

Subject

Neurology (clinical),Neurology

Link

https://link.springer.com/content/pdf/10.1007/s40120-021-00235-6.pdf

Reference36 articles.

1. Ando Y, Coelho T, Berk JL, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013;8:31.

2. Planté-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol. 2011;10:1086–97.